Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 53,000
-900 (-1.67%)
At close: Aug 6, 2025, 3:30 PM KST
Next Biomedical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
Operating Revenue | 10,945 | 9,543 | 4,882 | 2,795 | 2,267 | 2,261 | Upgrade |
Other Revenue | - | - | - | -0 | - | -0 | Upgrade |
| 10,945 | 9,543 | 4,882 | 2,795 | 2,267 | 2,261 | Upgrade | |
Revenue Growth (YoY) | 124.19% | 95.46% | 74.67% | 23.28% | 0.29% | 182.32% | Upgrade |
Cost of Revenue | 4,185 | 3,787 | 2,813 | 2,618 | 2,998 | 2,433 | Upgrade |
Gross Profit | 6,760 | 5,755 | 2,069 | 177.49 | -731.09 | -172.71 | Upgrade |
Selling, General & Admin | 2,991 | 2,610 | 2,407 | 2,246 | 2,866 | 1,994 | Upgrade |
Research & Development | 7,352 | 6,622 | 4,783 | 3,579 | 3,245 | 2,720 | Upgrade |
Other Operating Expenses | 24.07 | 21.51 | 20.04 | 19.29 | 18.39 | 10.61 | Upgrade |
Operating Expenses | 10,439 | 9,330 | 7,296 | 5,946 | 6,239 | 4,832 | Upgrade |
Operating Income | -3,679 | -3,575 | -5,226 | -5,768 | -6,970 | -5,004 | Upgrade |
Interest Expense | -494.84 | -520.06 | -574.37 | -360.41 | -1,413 | -1,535 | Upgrade |
Interest & Investment Income | 716.04 | 634.82 | 574.31 | 200.41 | 138.66 | 35.87 | Upgrade |
Currency Exchange Gain (Loss) | 905.27 | 1,128 | 0.56 | 63.63 | 90.33 | -77.31 | Upgrade |
Other Non Operating Income (Expenses) | 5,077 | 5,074 | -2,429 | 268.61 | -8,494 | -17,835 | Upgrade |
EBT Excluding Unusual Items | 2,525 | 2,742 | -7,655 | -5,596 | -16,648 | -24,416 | Upgrade |
Gain (Loss) on Sale of Investments | 264.91 | 113.58 | 133.56 | -102.48 | -65.86 | -34.61 | Upgrade |
Gain (Loss) on Sale of Assets | 4.24 | 4.24 | - | 5.29 | 69.58 | 0.1 | Upgrade |
Asset Writedown | - | - | - | -38.72 | -0.8 | -27.31 | Upgrade |
Pretax Income | 2,794 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 | Upgrade |
Net Income | 2,794 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 | Upgrade |
Net Income to Common | 2,794 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 | Upgrade |
Shares Outstanding (Basic) | 8 | 7 | 6 | 6 | 5 | 4 | Upgrade |
Shares Outstanding (Diluted) | 8 | 7 | 6 | 6 | 5 | 4 | Upgrade |
Shares Change (YoY) | 24.75% | 17.78% | 1.10% | 28.34% | 13.05% | 199.99% | Upgrade |
EPS (Basic) | 365.43 | 396.71 | -1198.00 | -923.00 | -3440.00 | -5719.00 | Upgrade |
EPS (Diluted) | -255.76 | -262.00 | -1198.00 | -923.00 | -3440.00 | -5719.00 | Upgrade |
Free Cash Flow | -939.25 | -1,640 | -4,225 | -8,403 | -6,101 | -4,003 | Upgrade |
Free Cash Flow Per Share | -119.92 | -221.77 | -672.87 | -1353.18 | -1260.87 | -935.17 | Upgrade |
Gross Margin | 61.76% | 60.31% | 42.38% | 6.35% | -32.25% | -7.64% | Upgrade |
Operating Margin | -33.61% | -37.46% | -107.05% | -206.37% | -307.42% | -221.36% | Upgrade |
Profit Margin | 25.53% | 29.97% | -154.06% | -205.07% | -734.13% | -1082.74% | Upgrade |
Free Cash Flow Margin | -8.58% | -17.18% | -86.53% | -300.65% | -269.08% | -177.05% | Upgrade |
EBITDA | -3,184 | -3,082 | -4,759 | -5,305 | -6,537 | -4,431 | Upgrade |
EBITDA Margin | -29.09% | -32.30% | -97.48% | -189.79% | -288.30% | -195.98% | Upgrade |
D&A For EBITDA | 494.76 | 492.36 | 467.32 | 463.41 | 433.53 | 573.79 | Upgrade |
EBIT | -3,679 | -3,575 | -5,226 | -5,768 | -6,970 | -5,004 | Upgrade |
EBIT Margin | -33.61% | -37.46% | -107.05% | -206.37% | - | -221.36% | Upgrade |
Advertising Expenses | - | 171.98 | 196.9 | 59.64 | 76.25 | 8 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.